Introduction
Experimental
Results
Discussion
| Entry | IC50 cell line HepG2 | IC50 cell line HT-29 |
|---|---|---|
| 1b | 10.37 | 12.45 |
| 1c | 10.33 | 11.05 |
| 5-Fluorouracil | 3.16 | 6.08 |
Authors
In this work, linear and cyclic disulfide heptapeptides of Longicalycinin A have been successfully synthesized by solid phase methodology with Fmoc /t-Bu and solution phase, respectively. 2-Chlorotrityl chloride resin (2-CTC) was used as a solid support. The synthesized linear disulfide analogue of Longicalycinin A was cleaved from the resin as a protected peptide. The final deprotection was performed by treatment with TFA 95% containing scavengers to achieve the deprotected linear disulfide analogue of Longicalycinin A which was characterized by different instrumental methods using LC-MS and FT-IR. Macrocyclization of deprotected linear peptide was done by an oxidating reagent. Linear and cyclic disulfide heptapeptides of Longicalycinin A were evaluated their toxic activity against cell lines of HepG2 and HT-29 using 3- (4, 5-dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide reagent in MTT assay. The synthetic analogues showed a relative good activity against cell lines of HepG2 and HT-29 with IC50 values from 10.33 µg/mL to 12.45 µg/mL, in comparison to the standard drug 5-fluorouracil (5-FU). Safety profiles of the synthesized linear and cyclic disulfide analogues of Longicalycinin A were also examined on skin fibroblast cells. Between the linear and cyclic disulfide heptapeptides of Longicalycinin A, the cyclic peptide showed a considerable toxic activity on the cancerous cell lines along with a low safety result on normal cells. Therefore, the linear disulfide heptapeptide of Longicalycinin A would be encouraging to develop new anticancer agents.
| Entry | IC50 cell line HepG2 | IC50 cell line HT-29 |
|---|---|---|
| 1b | 10.37 | 12.45 |
| 1c | 10.33 | 11.05 |
| 5-Fluorouracil | 3.16 | 6.08 |
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Baharloui M, Mirshokraee SA, Monfared A, Houshdar Tehrani MH. Design and Synthesis of Novel Triazole-based Peptide Analogues as Anticancer Agents. Iran J Pharm Res. 2019;18(3):e126183. doi: https://doi.org/10.22037/ijpr.2019.111722.13320
Dahiya R, Singh S, Varghese Gupta S, Sutariya VB, Bhatia D, et al. First Total Synthesis and Pharmacological Potential of a Plant Based Hexacyclopeptide. Iran J Pharm Res. 2019;18(2):e126237. doi: https://doi.org/10.22037/ijpr.2019.1100643
Shokri B, Zarghi A, Shahhoseini S, Mohammadi R, Kobarfard F. Design, Synthesis and Biological Evaluation of Ketoprofen Conjugated To RGD/NGR for Targeted Cancer Therapy. Iran J Pharm Res. 2018;17(4):e124878. doi: https://doi.org/10.22037/ijpr.2018.2317
Esfandiari Mazandaran K, Mirshokraee SA, Didehban K, Houshdar Tehrani MH. Design, Synthesis and Biological Evaluation of Ciprofloxacin- Peptide Conjugates as Anticancer Agents. Iran J Pharm Res. 2019;18(4):e124694. doi: https://doi.org/10.22037/ijpr.2019.111721.13319
Fatemi M, Ghandehari F, Bahrami S, Tajedin N. In Silico and in Vitro Studies of Cytotoxic Activity of Different Peptides Derived from Human Lactoferrin Protein. J Kermanshah Univ Med Sci. 2018;22(1):e69544. doi: https://doi.org/10.5812/jkums.69544
Last Update: 2 weeks ago
Last Update: 2 weeks ago
Last Update: 2 weeks ago
Last Update: 4 days ago